CIK 0001662774 · Non-accelerated filer<br>Smaller reporting company
IRulya Therapeutics Inc.
Sign in to watch- Ticker
- IRLA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 901024039
- Phone
- 203-208-8994
- Business address
- 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
- Former names
- Quince Therapeutics, Inc., Cortexyme, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 70 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-03 | McDowell Caryn Gordon Chief Legal & Adm. Officer | Grant or award | +140,000 | 140,000 | ||
| 2022-03-03 | LOWE CHRISTOPHER P. Interim CEO, COO & CFO | Grant or award | +175,000 | 265,000 | ||
| 2022-03-03 | Holsinger Leslie EVP, Preclinical Development | Grant or award | +155,500 | 159,000 | ||
| 2022-03-03 | Detke Michael J. Chief Medical Officer | Grant or award | +140,000 | 140,000 | ||
| 2022-01-03 | Lynch Casey Chief Executive Officer | Grant or award · Stock Option (right to buy) | +440,000 | 440,000 | ||
| 2022-01-03 | McDowell Caryn Gordon Chief Legal & Adm. Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2022-01-03 | LOWE CHRISTOPHER P. COO & Chief Financial Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2022-01-03 | Holsinger Leslie EVP, R&D | Grant or award · Stock option (right to buy) | +125,000 | 125,000 | ||
| 2022-01-03 | Dominy Stephen S. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 |
Page 8 of 8 · 149 trades